Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study

Table 4 Subgroup analysis of patients with daily urine protein < 1.73 g

	Group 1, Aggressive treatment (N = 45)	Group2, Supportive treatment (N = 10)	P value
Age at biopsy	50.2 [40.5–58.7]	50.9 [46.9–63.9]	0.294
Creatinine (mg/dL)	1.8 [1.4–2.4]	1.7 [1.5–2.3]	0.768
eGFR (ml/min/1.73m²)	33.2 [23.8–48.1]	30.9 [22.5–46.7]	0.751
Proteinuria (g/d)	0.3 [0.2–0.6]	0.5 [0.3–0.8]	0.111
Regimen
CsA based	10 (22.2%)	3 (30.0%)
FK-506 based	35 (77.8%)	7 (70.0%)
Drug level
CsA (ng/ml)	90.6 [86.4–115.0]	88.3 [84.2–96.5]	0.637
FK-506 (ng/ml)	5.3 [4.3–6.2]	5.2 [3.9–6.8]	0.959
Banff score
cg	1.0 [0.0–1.0]	1.0 [0.0–1.0]	0.683
ci + ct	2.0 [0.0–2.0]	2.0 [2.0–2.0]	0.269
mm	1.0 [1.0–2.0]	1.0 [1.0–2.0]	0.943
g + ptc	3.0 [2.0–4.0]	3.0 [2.0–3.0]	0.445

cg transplant glomerulopathy, ci interstitial fibrosis, ct tubular atrophy, mm mesangial matrix increase, g glomerulitis, ptc peritubular capillary inflammation

ISSN: 1471-2369